Bloomberg Law News: Patent Reform Bill Risks Higher Drug Prices and Delayed Generics
September 3, 2024
O’Melveny’s Coke Morgan Stewart authored a byline article in Bloomberg Law News on Tuesday, discussing the downsides of a drug patent reform bill. “Everyone wants drugs to be less expensive and more widely available,” she writes. “But this legislation won’t accomplish that goal. Just the opposite—the bill threatens to destabilize patent law and lead to fewer, more expensive drugs.”
Bloomberg Law News subscribers can read the full article here.